T-cell inactivation can result from interaction
LIBTAYO binds to PD-1 onT cells, blocking its interaction with PD-L1 and PD-L2 on tumor cells, helping to restore the antitumor T-cell response.1
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Burova E, Hermann A, Waite J, et al. Characterization of the anti–PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice. Mol Cancer Ther. 2017;16(5):861-870. 3. Never accept the status quo: R&D excellence in the biotech industry. Regeneron Pharmaceuticals, Inc. website. https://www.regeneron.com/technology. Accessed November 19, 2020.